Concepts (253)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 13 | 2025 | 75 | 2.040 |
Why?
|
| Antiviral Agents | 13 | 2025 | 100 | 1.370 |
Why?
|
| Hepatitis B, Chronic | 5 | 2023 | 33 | 1.360 |
Why?
|
| Hepatitis C | 7 | 2023 | 64 | 1.190 |
Why?
|
| Coronary Disease | 1 | 2025 | 146 | 0.880 |
Why?
|
| Hawaii | 14 | 2025 | 58 | 0.850 |
Why?
|
| Humans | 57 | 2025 | 17376 | 0.810 |
Why?
|
| Female | 46 | 2025 | 12444 | 0.780 |
Why?
|
| Stroke | 1 | 2025 | 310 | 0.770 |
Why?
|
| Liver Cirrhosis | 6 | 2024 | 41 | 0.760 |
Why?
|
| Sustained Virologic Response | 6 | 2023 | 19 | 0.700 |
Why?
|
| Male | 31 | 2025 | 9843 | 0.650 |
Why?
|
| Quality of Life | 4 | 2023 | 505 | 0.620 |
Why?
|
| Middle Aged | 27 | 2025 | 7885 | 0.610 |
Why?
|
| Stress, Psychological | 1 | 2020 | 133 | 0.600 |
Why?
|
| Health Status | 1 | 2020 | 295 | 0.570 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2023 | 29 | 0.560 |
Why?
|
| Suicide | 3 | 2024 | 116 | 0.550 |
Why?
|
| Aged | 19 | 2025 | 6129 | 0.550 |
Why?
|
| Liver Neoplasms | 3 | 2023 | 42 | 0.540 |
Why?
|
| Risk Factors | 13 | 2025 | 3255 | 0.540 |
Why?
|
| Adult | 25 | 2025 | 7529 | 0.540 |
Why?
|
| Lung Neoplasms | 3 | 2025 | 270 | 0.500 |
Why?
|
| Hepacivirus | 9 | 2024 | 52 | 0.480 |
Why?
|
| Mental Disorders | 3 | 2022 | 273 | 0.450 |
Why?
|
| Retrospective Studies | 9 | 2025 | 2428 | 0.450 |
Why?
|
| Patient Health Questionnaire | 2 | 2024 | 18 | 0.430 |
Why?
|
| Incidence | 8 | 2025 | 1266 | 0.430 |
Why?
|
| Liver Cirrhosis, Biliary | 2 | 2025 | 4 | 0.410 |
Why?
|
| Cataract Extraction | 1 | 2012 | 3 | 0.390 |
Why?
|
| Cataract | 1 | 2012 | 12 | 0.380 |
Why?
|
| Adolescent | 20 | 2024 | 3533 | 0.370 |
Why?
|
| Rural Population | 1 | 2012 | 55 | 0.370 |
Why?
|
| United States | 13 | 2024 | 3891 | 0.370 |
Why?
|
| Prevalence | 5 | 2023 | 839 | 0.360 |
Why?
|
| Coinfection | 2 | 2023 | 31 | 0.340 |
Why?
|
| Hepatitis B | 2 | 2023 | 45 | 0.340 |
Why?
|
| Mental Health | 2 | 2023 | 168 | 0.330 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 2 | 2022 | 12 | 0.330 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 2 | 2007 | 5 | 0.320 |
Why?
|
| Diet | 3 | 2007 | 356 | 0.320 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2019 | 666 | 0.280 |
Why?
|
| Absorptiometry, Photon | 4 | 2011 | 51 | 0.280 |
Why?
|
| Cohort Studies | 12 | 2024 | 2526 | 0.280 |
Why?
|
| Self-Injurious Behavior | 2 | 2024 | 44 | 0.270 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2006 | 7 | 0.250 |
Why?
|
| Feeding Behavior | 2 | 2007 | 163 | 0.250 |
Why?
|
| California | 4 | 2025 | 2317 | 0.240 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2025 | 26 | 0.240 |
Why?
|
| Alkaline Phosphatase | 1 | 2025 | 9 | 0.240 |
Why?
|
| Heart Failure | 2 | 2025 | 404 | 0.240 |
Why?
|
| Breast Neoplasms | 5 | 2017 | 977 | 0.240 |
Why?
|
| Mastitis | 1 | 2024 | 2 | 0.230 |
Why?
|
| Hepatitis B virus | 3 | 2023 | 25 | 0.230 |
Why?
|
| Clozapine | 1 | 2024 | 6 | 0.220 |
Why?
|
| International Classification of Diseases | 1 | 2024 | 86 | 0.220 |
Why?
|
| Obesity | 3 | 2024 | 814 | 0.220 |
Why?
|
| Body Mass Index | 4 | 2022 | 937 | 0.220 |
Why?
|
| Aminoisobutyric Acids | 1 | 2024 | 2 | 0.220 |
Why?
|
| Cyclopropanes | 1 | 2024 | 2 | 0.220 |
Why?
|
| Lactams, Macrocyclic | 1 | 2024 | 2 | 0.220 |
Why?
|
| Benzimidazoles | 1 | 2024 | 6 | 0.220 |
Why?
|
| Proline | 1 | 2024 | 6 | 0.220 |
Why?
|
| Sulfonamides | 1 | 2024 | 15 | 0.220 |
Why?
|
| Leucine | 1 | 2024 | 5 | 0.220 |
Why?
|
| Adipose Tissue | 5 | 2011 | 65 | 0.220 |
Why?
|
| Antipsychotic Agents | 1 | 2024 | 49 | 0.210 |
Why?
|
| ras Proteins | 2 | 2014 | 20 | 0.210 |
Why?
|
| Psychotic Disorders | 1 | 2024 | 49 | 0.210 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2014 | 32 | 0.210 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2023 | 10 | 0.200 |
Why?
|
| Latent Tuberculosis | 1 | 2023 | 11 | 0.200 |
Why?
|
| African Americans | 3 | 2020 | 443 | 0.200 |
Why?
|
| Opportunistic Infections | 1 | 2022 | 7 | 0.200 |
Why?
|
| Ribavirin | 2 | 2019 | 8 | 0.200 |
Why?
|
| Breast | 3 | 2011 | 84 | 0.190 |
Why?
|
| Carbonated Beverages | 3 | 2007 | 15 | 0.190 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 274 | 0.180 |
Why?
|
| Surveys and Questionnaires | 4 | 2022 | 1287 | 0.180 |
Why?
|
| Multivariate Analysis | 3 | 2020 | 538 | 0.180 |
Why?
|
| Pregnancy Outcome | 1 | 2022 | 158 | 0.180 |
Why?
|
| Weight Gain | 1 | 2022 | 156 | 0.180 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 205 | 0.180 |
Why?
|
| Young Adult | 7 | 2024 | 2473 | 0.170 |
Why?
|
| Overweight | 1 | 2022 | 266 | 0.170 |
Why?
|
| Psychology | 1 | 2020 | 14 | 0.170 |
Why?
|
| Autism Spectrum Disorder | 1 | 2023 | 159 | 0.170 |
Why?
|
| Cholagogues and Choleretics | 1 | 2020 | 2 | 0.170 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2020 | 2 | 0.170 |
Why?
|
| Physician's Role | 1 | 2020 | 26 | 0.170 |
Why?
|
| Psychiatry | 1 | 2020 | 22 | 0.170 |
Why?
|
| Unemployment | 1 | 2020 | 12 | 0.170 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 21 | 0.160 |
Why?
|
| Electronic Health Records | 1 | 2024 | 707 | 0.160 |
Why?
|
| Prospective Studies | 5 | 2023 | 1229 | 0.150 |
Why?
|
| Treatment Outcome | 5 | 2024 | 1170 | 0.150 |
Why?
|
| Puberty | 2 | 2011 | 58 | 0.150 |
Why?
|
| China | 2 | 2024 | 132 | 0.150 |
Why?
|
| Mental Health Services | 1 | 2020 | 154 | 0.150 |
Why?
|
| Social Support | 1 | 2020 | 208 | 0.150 |
Why?
|
| Virus Activation | 1 | 2018 | 5 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 47 | 0.140 |
Why?
|
| Time Factors | 5 | 2019 | 1044 | 0.140 |
Why?
|
| Comorbidity | 1 | 2020 | 564 | 0.140 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 533 | 0.140 |
Why?
|
| Child | 8 | 2023 | 2382 | 0.140 |
Why?
|
| Neoplasms | 1 | 2022 | 448 | 0.140 |
Why?
|
| Risk Assessment | 5 | 2024 | 1079 | 0.140 |
Why?
|
| Liver | 1 | 2017 | 34 | 0.140 |
Why?
|
| Pregnancy | 1 | 2022 | 1466 | 0.140 |
Why?
|
| Gene Library | 1 | 2017 | 4 | 0.140 |
Why?
|
| Paraffin Embedding | 1 | 2017 | 5 | 0.140 |
Why?
|
| Calcium, Dietary | 3 | 2007 | 28 | 0.140 |
Why?
|
| Colorectal Neoplasms | 2 | 2014 | 627 | 0.140 |
Why?
|
| Health Policy | 1 | 2018 | 109 | 0.140 |
Why?
|
| Suicidal Ideation | 3 | 2024 | 96 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 32 | 0.140 |
Why?
|
| Suicide, Attempted | 1 | 2018 | 92 | 0.130 |
Why?
|
| MicroRNAs | 1 | 2017 | 17 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 380 | 0.130 |
Why?
|
| Menarche | 2 | 2009 | 28 | 0.130 |
Why?
|
| Tuberculosis | 1 | 2017 | 24 | 0.130 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2017 | 52 | 0.130 |
Why?
|
| Viral Load | 1 | 2017 | 135 | 0.130 |
Why?
|
| Population Surveillance | 1 | 2018 | 254 | 0.130 |
Why?
|
| Sex Distribution | 2 | 2017 | 180 | 0.130 |
Why?
|
| Age Distribution | 2 | 2017 | 239 | 0.130 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 1287 | 0.120 |
Why?
|
| Aged, 80 and over | 5 | 2019 | 1942 | 0.110 |
Why?
|
| Cause of Death | 3 | 2021 | 175 | 0.110 |
Why?
|
| Age Factors | 4 | 2019 | 884 | 0.100 |
Why?
|
| ErbB Receptors | 1 | 2012 | 5 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 7 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2015 | 239 | 0.100 |
Why?
|
| Skinfold Thickness | 3 | 2006 | 17 | 0.090 |
Why?
|
| Minority Groups | 2 | 2023 | 103 | 0.090 |
Why?
|
| Biomarkers | 2 | 2025 | 306 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2012 | 140 | 0.090 |
Why?
|
| Prognosis | 3 | 2020 | 604 | 0.080 |
Why?
|
| Iron, Dietary | 2 | 2007 | 8 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2022 | 1100 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2025 | 1155 | 0.080 |
Why?
|
| Dietary Fiber | 2 | 2007 | 60 | 0.080 |
Why?
|
| Depression | 2 | 2024 | 487 | 0.080 |
Why?
|
| Asian Americans | 2 | 2020 | 164 | 0.070 |
Why?
|
| Nutritional Requirements | 1 | 2007 | 4 | 0.070 |
Why?
|
| Body Fat Distribution | 1 | 2007 | 4 | 0.070 |
Why?
|
| Dietary Sucrose | 1 | 2007 | 13 | 0.070 |
Why?
|
| Nutrition Policy | 1 | 2007 | 19 | 0.070 |
Why?
|
| Skin | 1 | 2007 | 13 | 0.070 |
Why?
|
| Sunlight | 1 | 2007 | 13 | 0.070 |
Why?
|
| Vitamin D Deficiency | 1 | 2007 | 20 | 0.070 |
Why?
|
| European Continental Ancestry Group | 2 | 2020 | 480 | 0.060 |
Why?
|
| Vitamin D | 1 | 2007 | 72 | 0.060 |
Why?
|
| Smoking | 2 | 2022 | 428 | 0.060 |
Why?
|
| Survival Rate | 2 | 2020 | 253 | 0.060 |
Why?
|
| Asia | 1 | 2006 | 12 | 0.060 |
Why?
|
| Folic Acid | 1 | 2006 | 29 | 0.060 |
Why?
|
| Diet Surveys | 1 | 2006 | 56 | 0.060 |
Why?
|
| Mitochondria | 1 | 2025 | 8 | 0.060 |
Why?
|
| Lactation | 1 | 2024 | 34 | 0.060 |
Why?
|
| Milk | 1 | 2004 | 8 | 0.060 |
Why?
|
| Longitudinal Studies | 3 | 2018 | 677 | 0.060 |
Why?
|
| Smoke | 1 | 2024 | 6 | 0.060 |
Why?
|
| Pyrrolidines | 1 | 2024 | 2 | 0.050 |
Why?
|
| Pruritus | 1 | 2023 | 3 | 0.050 |
Why?
|
| Quinoxalines | 1 | 2024 | 12 | 0.050 |
Why?
|
| Bone Density | 1 | 2004 | 94 | 0.050 |
Why?
|
| Infant Formula | 1 | 2003 | 9 | 0.050 |
Why?
|
| Fatigue | 1 | 2023 | 32 | 0.050 |
Why?
|
| Schizophrenia | 1 | 2024 | 76 | 0.050 |
Why?
|
| Logistic Models | 2 | 2019 | 884 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2014 | 21 | 0.050 |
Why?
|
| Genotype | 1 | 2024 | 223 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 702 | 0.050 |
Why?
|
| Population Groups | 1 | 2023 | 7 | 0.050 |
Why?
|
| Body Weight | 1 | 2004 | 203 | 0.050 |
Why?
|
| Health Promotion | 1 | 2006 | 278 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2024 | 144 | 0.050 |
Why?
|
| Genetic Testing | 2 | 2014 | 70 | 0.050 |
Why?
|
| Mutation | 2 | 2014 | 132 | 0.050 |
Why?
|
| Child Health | 1 | 2023 | 39 | 0.050 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2022 | 7 | 0.050 |
Why?
|
| Exercise | 2 | 2004 | 513 | 0.050 |
Why?
|
| Regression Analysis | 3 | 2007 | 280 | 0.040 |
Why?
|
| Liver Transplantation | 1 | 2020 | 6 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 14 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 23 | 0.040 |
Why?
|
| Health Surveys | 1 | 2020 | 250 | 0.040 |
Why?
|
| Bilirubin | 1 | 2020 | 31 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2020 | 73 | 0.040 |
Why?
|
| Oceanic Ancestry Group | 1 | 2020 | 33 | 0.040 |
Why?
|
| Mammography | 2 | 2011 | 168 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2019 | 65 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 107 | 0.040 |
Why?
|
| Interferons | 1 | 2019 | 5 | 0.040 |
Why?
|
| Washington | 1 | 2020 | 385 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2019 | 43 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 644 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2023 | 1375 | 0.040 |
Why?
|
| Hospitalization | 1 | 2024 | 805 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 47 | 0.040 |
Why?
|
| Glycated Hemoglobin A | 1 | 2019 | 184 | 0.040 |
Why?
|
| Hispanic Americans | 1 | 2020 | 378 | 0.040 |
Why?
|
| Fibrosis | 1 | 2017 | 7 | 0.030 |
Why?
|
| Risk-Taking | 1 | 2018 | 103 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2017 | 4 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2019 | 315 | 0.030 |
Why?
|
| Ethnic Groups | 1 | 2020 | 456 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2017 | 41 | 0.030 |
Why?
|
| Antidepressive Agents | 1 | 2018 | 142 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 609 | 0.030 |
Why?
|
| Health Behavior | 1 | 2018 | 345 | 0.030 |
Why?
|
| Body Composition | 2 | 2007 | 91 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 607 | 0.030 |
Why?
|
| Pacific States | 1 | 2015 | 4 | 0.030 |
Why?
|
| Mass Screening | 1 | 2020 | 671 | 0.030 |
Why?
|
| Educational Status | 1 | 2015 | 179 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 31 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2015 | 53 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 84 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 114 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2019 | 729 | 0.030 |
Why?
|
| Continental Population Groups | 1 | 2015 | 289 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 341 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 100 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 120 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 58 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 231 | 0.020 |
Why?
|
| Family Health | 1 | 2011 | 45 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 211 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 300 | 0.020 |
Why?
|
| Mothers | 1 | 2011 | 103 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 367 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2012 | 253 | 0.020 |
Why?
|
| Polynesia | 1 | 2009 | 2 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2007 | 23 | 0.020 |
Why?
|
| Dietary Proteins | 1 | 2007 | 19 | 0.020 |
Why?
|
| Dietary Carbohydrates | 1 | 2007 | 28 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 47 | 0.020 |
Why?
|
| Diet Records | 1 | 2007 | 37 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 2007 | 6 | 0.020 |
Why?
|
| Energy Intake | 1 | 2007 | 98 | 0.020 |
Why?
|
| Dietary Fats | 1 | 2007 | 89 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2007 | 119 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2004 | 56 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2004 | 82 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2003 | 37 | 0.010 |
Why?
|
| Anthropometry | 1 | 2003 | 60 | 0.010 |
Why?
|
| Animals | 1 | 2004 | 280 | 0.010 |
Why?
|
| Aging | 1 | 2003 | 160 | 0.010 |
Why?
|
| Breast Feeding | 1 | 2003 | 113 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2003 | 805 | 0.010 |
Why?
|
Concepts
(253)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(22)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
-->